### 1 AD PLASMA BIOMARKERS ARE STABLE FOR AN EXTENDED PERIOD AT -20°C: IMPLICATIONS

#### 2 FOR RESOURCE-CONSTRAINED ENVIRONMENTS.

- Biniyam A. Ayele<sup>1,2</sup>, Patrice L. Whitehead<sup>1</sup>, Julianna Pascual<sup>1</sup>, Tianjie Gu<sup>1</sup>, Jamie Arvizu<sup>1</sup>, Charles
- 4 G. **Golightly**<sup>1</sup>, Larry D. **Adams**<sup>1</sup>, Margaret A. **Pericak-Vance**<sup>1,3,4</sup>, Jeffery M. **Vance**<sup>1,3,4</sup>, Anthony J.
- 5 **Griswold**<sup>1,3\*</sup>
- <sup>6</sup> <sup>1</sup> John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine,
- 7 Miami, FL.
- <sup>2</sup> Department of Neurology, CHS, Addis Ababa University, Addis Ababa, Ethiopia
- 9 <sup>3</sup> Dr. John T Macdonald Foundation Department of Human Genetics, University of Miami Miller
- 10 School of Medicine, Miami, FL.
- <sup>4</sup> Department of Neurology, University of Miami Miller School of Medicine, Miami, FL
- 12 **Running title:** Stability of AD blood based biomarkers
- 13 Word counts: 1915
- 14 **Correspondence:**
- 15 Anthony J. Griswold, PhD, Associate Professor of Human Genetics
- 16 The Dr. John T. Macdonald Foundation Department of Human Genetics
- 17 John P. Hussman Institute for Human Genomics
- 18 Associate Director, Center for Genome Technology, University of Miami Miller School of
- 19 Medicine
- 20 1501 NW 10th Avenue (M-860), BRB 318 Miami, FL 33136 (305) 243-5982 (office)

## 21 agriswold@med.miami.ed

## 22 ABSTRACT

23	Standard procedures for measuring Alzheimer's disease (AD) plasma biomarkers include storage
24	at -80°C. This is challenging in countries lacking research infrastructure, such -80°C freezer. To
25	investigate stability of AD biomarkers from plasma stored at -20°C, we compared aliquots stored
26	at -80°C and others at -20°C for two, four, six, fifteen, and thirty-five weeks. pTau181, A $\beta$ 42,
27	A $\beta$ 40, NfL, and GFAP were measured for each timepoint. pTau181 and A $\beta$ 42/A $\beta$ 40 ratios
28	showed minimal variation for up to 15 weeks. NfL and GFAP had higher variability. This finding
29	of 15-week stability at -20°C enables greater participation in AD biomarker studies in resource
30	constrained environments.

31

32 **Keywords:** Alzheimer's disease; blood-based biomarkers; stability; resource-constrained

33

#### 34 **INTRODUCTION**

Globally, Alzheimer's disease (AD) is the most common cause of dementia accounting for 60%-80% of all cases [1–4]. Over 60% of AD patients reside in low- and middle-income countries (LMIC) with exponential increase in prevalence expected by mid-century [1–4]. AD is characterized by the extracellular deposition of beta amyloid plaques and intracellular deposition of neurofibrillary tau tangles, which gradually result in damage and loss of neuronal cells [5,6]. Current gold standard diagnostic methods to confirm the presence of amyloid beta and tau deposition in the brain are advanced imaging techniques such as amyloid-PET and tau-

PET scans or measurement of cerebrospinal fluid (CSF) based biomarkers such as amyloid-β or phosphorylated Tau [7–10]. However, given the invasive and expensive nature of these tests, their use in resource constrained settings is prohibitive. However, blood-based biomarkers (BBM) show potential for aiding in the early and accurate detection of AD neuropathology and identifying presymptomatic or mild cognitive impairment (MCI) stages of AD cases [11–15]. Thus, plasma biomarkers could offer cost-effective, easily accessible, and scalable AD diagnostic options for widespread use in resource constrained settings [7, 16].

49 While plasma isolation is minimally invasive and low cost, appropriate preanalytical handling is critical to limit variability in measurements. As recommended by the Standardization 50 51 of Alzheimer's Blood Biomarkers (SABB) working group of the Alzheimer's Association, plasma 52 should be stored immediately at -20°C for a maximum of two weeks with longer term storage at -80°C [17]. Such a requirement is challenging in low-resource settings where -80°C storage is not 53 54 readily available nor is shipping of frozen aliguots practical or cost effective. An example of this 55 challenge presents itself in the DAWN study, a multi-center project funded by the National 56 Institute on Aging (NIA). DAWN aims to explore AD in diverse ancestral groups including nine 57 countries from sub-Saharan Africa (SSA) through the Africa Dementia Consortium (AfDC) [18]. 58 This involves collection of detailed clinical and neuropsychological data and blood samples from 5000 indigenous Africans for genomic and biomarkers investigation. Critically, of the nine 59 countries participating in the DAWN study from Africa, only three have local access to -80°C 60 61 freezers, though all have access to -20°C storage.

62 While previous studies have indicated that intermittent storage of plasma samples at -63 20°C for 2 weeks does not change biomarker levels [17], no study has shown stability of BBM

beyond two weeks. Herein we investigate the stability of biomarker measures of phosphorylated threonine-181 of Tau (pTau181), amyloid-β 40 & 42 (Aβ40 and Aβ42), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) from plasma stored at -20°C for 2, 4, 6, 15, or 35 week timepoints. This approach could simplify plasma studies and storage, particularly beneficial to enhance AD research in resource-limited settings, without significantly compromising the integrity of the biomarker measurements.

#### 70 <u>METHODS</u>

### 71 Study setting and ethical considerations:

The study was conducted at the John P. Hussman Institute for Human Genomics (HIHG) at the University of Miami, Miller School of Medicine. The study was performed on the blood samples obtained from ten anonymous healthy volunteers. Appropriate study ethical approval was obtained from the University of Miami ethical review board, and all the volunteers gave a written consent before the samples were collected.

### 77 Sample collection and handling:

Peripheral blood samples were collected from ten volunteers via venipuncture using a 21G needle and collected into ethylene diamine tetraacetic acid (EDTA) tubes. Plasma was isolated within 15 minutes of venipuncture via centrifugation for 10 min at 1,800 × g at room temperature (RT) and 250mL plasma aliquots were made into prelabeled barcoded polypropylene storage tubes. Two aliquots per participant were stored within 60 minutes at -80°C and the others at -20°C for 2, 4, 6, and 15 weeks before transfer to -80°C and biomarker

analysis (Figure 1). A subset of four individuals had enough plasma aliquots to extend storage to
35 weeks before transfer to -80°C.

86

87

#### 88 Sample analysis:

Measurement of BBM was performed for a baseline measure from the aliquot stored at -80°C and from those stored for 2, 4, 6, 15, and 35 weeks before transfer from -20°C to -80°C. We then measured concentration of pTau181, Aβ42, Aβ40, NfL, and GFAP with Single molecule arrays (Simoa<sup>™</sup>) chemistry using the pTau181 AdvantageV2 and NEUROLOGY 4-PLEX E assays on the Quanterix HD-X [19]. Initial data analysis was performed using the Quanterix Analyzer v1.6 software to calculate standard curves and biomarker concentrations. Each aliquot was run in duplicate on the assay plate.

#### 96 **Statistical analysis**

97 The percentage change of plasma AD biomarker levels at 2, 4, 6, 15, and 35 weeks compared to 98 the baseline were calculated for each individual. The aggregate mean value and percentage 99 changes of each of the biomarkers at different timepoint were compared with the mean value 100 at the baseline for each of the study participants. We considered percentage change of +/- 10 % as a cutoff point to define clinically significant changes for pTau181, AB42, and AB40 as 101 102 previously suggested [17]. Variability for NfL and GFAP can be upwards of 10% within a run for 103 the same sample as reported, suggesting that higher cutoff points are applicable for these assays (Simoa<sup>®</sup> Neurology 4-Plex E). 104

#### 105 <u>**RESULTS**</u>

Figure 2 summarizes the percentage changes of the mean values of each biomarker assayed over time stored at -20°C before transfer to -80°C. There was a minimal mean percentage changes for pTau181 compared to the baseline from weeks 2 through 15, with mean change of <10% over the four timepoints with a noticeable decline of nearly 33% in aliquots stored for 35 weeks. The average level of A $\beta$ 42/A $\beta$ 40 ratio was stable over all study timepoints showing an overall 5% reduction compared to the baseline. However, the individual measures of A $\beta$ 42 and A $\beta$ 40 showed higher variability at the 15-week and 35-week timepoints.

Higher variability was observed in the concentration of GFAP and NfL at all five timepoints. We observed a consistent increase in concentration of NfL at all timepoints compared to the baseline, ranging from 11% increment at week 2 to 25% increment at week 35 compared to the baseline measurement. Similar variability was observed in the level of GFAP over the five timepoints. The overall variability of GFAP ranged from 7% at week 2 to 29% at week 35 compared to the baseline value.

We have analyzed the observed variation by individual samples at various timepoints to understand the individual level variations. The concentration of pTau181 was stable in over the five time points in 8 of the study participants. In two of the samples (202301377 and 202301372) pTau181 showed greater than 10% variability at week 2, week 6, and week 35 respectively. Aβ42 and Aβ40 showed relatively consistent stability in concentration in all 10 samples at all timepoints. GFAP and NfL concentration show variations across all samples with a general increase over time (Figure 3).

#### 126 **DISCUSSION**

127 The investigation of Alzheimer's disease plasma biomarkers among diverse ancestry populations has been extremely limited, though increasingly studies including African 128 129 Americans and Hispanic/Latino individuals from the US have emerged[20–25]. In particular, there are nearly no studies in sub-Saharan Africa, with one recent study from the Democratic 130 Republic of Congo (DRC) a notable exception [26]. At least one barrier to inclusion of African 131 132 participants in biomarker study has been the availability of research infrastructure to support the existing best practices [17]. Africa, and other low and middle income countries often lack -133 80°C freezer storage due to cost of the instrumentation, reliability of the power grid, and cost of 134 135 backup and solar power. Furthermore, logistics for short term storage and shipping to central repositories are hindered by lack of shipping infrastructure and availability of cold storage 136 137 materials such as dry ice or liquid nitrogen. Thus, this study investigated the stability of AD BBM 138 from plasma stored at -20°C for at timepoints beyond the current recommendation of 2 weeks. Overall, after 15 weeks of storage at -20°C, the mean levels of pTau181 and the Aβ42/Aβ40 ratio 139 showed minimal variation compared to baseline, indicating their reliability for analysis in these 140 settings. However, the level of pTau181 dropped significantly at week 35. Moreover, the mean 141 concentrations of NfL and GFAP showed greater variability and increased over time points, 142 although the overall deviations of NfL and GFAP remained within acceptable manufacturer 143 limits, i.e. as much as 10% variability in duplicate runs. 144

To date, no study has investigated the stability of BBM past two weeks at -20°C freezer. Verberk et al 2022, has reported concentration of pTau181 is resistance to delayed centrifugation (24hrs) and storage at higher temperature (-20°C) for up to two weeks [17].

Despite the observed drop in the level of pTau181 at week 35, our observation supports the 148 149 stability of pTau when stored in -20°C freezer up to week 15, making its usability practical in resource limited setting where the availability of a deep freezer is limited. Similarly, the 150 Aβ42/Aβ40 ratio was stable over the measured timepoints with mild reduction from the 151 152 baseline concentration. Finally, our study showed fluctuations in the concentrations of GFAP and NfL across all five measurement timepoints when compared to the baseline levels. Both the 153 level of GFAP and NfL start increasing in the second week and maximal change from the 154 baseline was observed at week 35. 155

In the present study, the overall mean concentration of pTau181 and the AB42/AB40 156 157 ratio were comparable to a recent study by Griswold et al. 2024, [24] published on MedRxiv. The 158 study examined AD blood biomarker profiles in 2,086 individuals from diverse genetic backgrounds, aiming to identify biomarker variations among different populations. Likewise, the 159 mean pTau181 levels were 1.98 pg/mL and 2.02 pg/mL for African Americans , and 1.84 pg/mL 160 for Caribbean Hispanics . Additionally, they reported mean AB42/AB40 ratios of 0.0477 and 161 0.0575 for African Americans and 0.0432 for Caribbean Hispanics. These findings closely align 162 163 with the aggregate mean concentrations observed in our study [24].

The underlying biological, chemical, or physical factors driving these deviations remain unknown and have varied across studies. Our finding is congruent with a study by Lewczuk et al. 2018, which reported the concentration of NfL increases when samples are stored even for five days at higher temperature such as room temperature or at 4 degrees [27]. However, Verbeck et al 2022, has reported they haven't seen such an increase in level of NfL after two weeks storage in refrigerator. Furthermore, Altmann et al. 2020 reported the serum level of NfL is resistant to

delayed centrifugation (24hrs) and up to three thawing and re-freezing cycles [28]. Whether
these variabilities are due to biological factors such as protein aggregation, chemical factors
such as assay performances, or physical features such as binding to sides of tubes remains to be
investigated.

174 In summary, up to 15 weeks of storage of plasma at -20°C does not significantly change 175 AD related plasma biomarker concentrations beyond assay specifications, though there are 176 modest increases in GFAP and NfL in all timepoints. This suggests that locations lacking -80°C 177 storage can utilize -20°C equipment and still maintain biomarker fidelity, allowing for greater 178 representation of biomarker studies from low- and middle- income countries, increasing the 179 diversity of studies in AD.

Acknowledgement: The authors are grateful to all the ten volunteers who donated their bloodto this study.

182 **Funding:** AG074865, AG072547, AG076482, AG062943, AG057659, AG066767

- 183 Conflict of interest: none
- 184 **Consent to publish:** Not applicable.

185 Data Availability: The raw dataset used for this study's conclusion can be accessed upon 186 reasonable request from the corresponding and senior author.

187 There are no sources in the current document.

188 **Reference:** 

189	1.	World Health Organization. Global action plan on the public health response to
190		dementia 2017–2025. World Health Organization; 2017.
191	2.	Nichols E, Steinmetz JD, Vollset SE, et al. Estimation of the global prevalence of dementia
192		in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease
193		Study 2019. Lancet Public Health. 2022;7(2):e105–25.
194	3.	Rizzi L, Rosset I, Roriz-Cruz M. Global Epidemiology of Dementia: Alzheimer's and
195		Vascular Types. <i>BioMed Res Int.</i> 2014;1–8.
196	4.	Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M. World Alzheimer Report 2015.
197		The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends.
198	5.	DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease. Mol
199		Neurodegener. 2019;14(1):32.
200	6.	Bloom GS. Amyloid- $\beta$ and Tau: The Trigger and Bullet in Alzheimer Disease Pathogenesis.
201		JAMA Neurol. 2014;71(4):505.
202	7.	Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood-based biomarkers for Alzheimer's
203		disease: towards clinical implementation. <i>Lancet Neurol</i> . 2022;21(1):66–77.
204	8.	Walhovd KB, Fjell AM, Brewer J, et al. Combining MR Imaging, Positron-Emission
205		Tomography, and CSF Biomarkers in the Diagnosis and Prognosis of Alzheimer Disease.
206		Am J Neuroradiol. 2010;31(2):347–54.

207	9.	Palmqvist S, Zetterberg H, Mattsson N, et al. Detailed comparison of amyloid PET and
208		CSF biomarkers for identifying early Alzheimer disease. <i>Neurology</i> . 2015;85(14):1240–9.
209	10.	Hameed S, Fuh JL, Senanarong V, et al. Role of Fluid Biomarkers and PET Imaging in Early
210		Diagnosis and its Clinical Implication in the Management of Alzheimer's Disease. J
211		Alzheimers Dis Rep. 2020;4(1):21–37.
212	11.	Shen X, Li J, Wang H, Li H, et al. Plasma amyloid, tau, and neurodegeneration biomarker
213		profiles predict Alzheimer's disease pathology and clinical progression in older adults
214		without dementia. Alzheimers Dement Diagn Assess Dis Monit. 2020;12(1).
215	12.	Mattsson N, Andreasson U, Zetterberg H, et al. Association of Plasma Neurofilament
216		Light With Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol
217		;74(5):557.
218	13.	lack CB Bennett DA Blennow K et al A/T/N: An unbiased descriptive classification
219		scheme for Alzheimer disease biomarkers. <i>Neurology</i> . 2016;87(5):539–47.
219 220	14.	scheme for Alzheimer disease biomarkers. <i>Neurology.</i> 2016;87(5):539–47. Yu J, Li J, Suckling J, et al. Frequency and longitudinal clinical outcomes of Alzheimer's
219 220 221	14.	scheme for Alzheimer disease biomarkers. <i>Neurology.</i> 2016;87(5):539–47. Yu J, Li J, Suckling J, et al. Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal study. <i>Alzheimers Dement.</i> 2019;15(9):1208–17.
219 220 221 222	14. 15.	scheme for Alzheimer disease biomarkers. <i>Neurology</i> . 2016;87(5):539–47. Yu J, Li J, Suckling J, et al. Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal study. <i>Alzheimers Dement</i> . 2019;15(9):1208–17. Park JC, Han SH, Yi D, et al. Plasma tau/amyloid-β1–42 ratio predicts brain tau deposition
219 220 221 222 222 223	14. 15.	scheme for Alzheimer disease biomarkers. <i>Neurology</i> . 2016;87(5):539–47. Yu J, Li J, Suckling J, et al. Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal study. <i>Alzheimers Dement</i> . 2019;15(9):1208–17. Park JC, Han SH, Yi D, et al. Plasma tau/amyloid-β1–42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease. <i>Brain</i> . 2019;142(3):771–86.
<ul> <li>219</li> <li>220</li> <li>221</li> <li>222</li> <li>223</li> <li>224</li> </ul>	14. 15. 16.	scheme for Alzheimer disease biomarkers. <i>Neurology</i> . 2016;87(5):539–47. Yu J, Li J, Suckling J, et al. Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal study. <i>Alzheimers Dement</i> . 2019;15(9):1208–17. Park JC, Han SH, Yi D, et al. Plasma tau/amyloid-β1–42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease. <i>Brain</i> . 2019;142(3):771–86. Agarwal M, Khan S. Plasma lipids as biomarkers for Alzheimer's disease: a systematic

226	17.	Verberk IMW, Misdorp EO, Koelewijn J, et al. Characterization of pre-analytical sample
227		handling effects on a panel of Alzheimer's disease-related blood-based biomarkers:
228		Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working
229		group. Alzheimers Dement J Alzheimers Assoc. 2022;18(8):1484–97.
230	18.	Akinyemi RO, Owolabi MO, Okubadejo N, et al. The African Dementia Consortium.
231		Lancet Neurol. 2023;22(1):28–9.
232	19.	Wilson DH, Rissin DM, Kan CW, et al. The Simoa HD-1 Analyzer: A Novel Fully Automated
233		Digital Immunoassay Analyzer with Single-Molecule Sensitivity and Multiplexing. SLAS
234		Technol. 2016;21(4):533–47.
235	20.	Jiang X, Bahorik AL, Graff-Radford NR, et al. Association of Plasma Amyloid- $eta$ and
236		Dementia Among Black and White Older Adults. <i>J Alzheimers Dis.</i> 2024;99(2):787–97.
237	21.	Windon C, laccarino L, Mundada N, et al. Comparison of plasma and CSF biomarkers
238		across ethnoracial groups in the ADNI. Alzheimers Dement Diagn Assess Dis Monit.
239		2022;14(1):e12315.
240	22.	Deniz K, Ho CCG, Malphrus KG, et al. Plasma Biomarkers of Alzheimer's Disease in
241		African Americans. J Alzheimers Dis. 2021;79(1):323–34.
242	23.	Molina-Henry DP, Raman R, Liu A, et al. Racial and ethnic differences in plasma
243		biomarker eligibility for a preclinical Alzheimer's disease trial. Alzheimers Dement.
244		2024;20(6):3827–38.

245	24.	Griswold AJ, Rajabli F, Gu T, et al. Generalizability of Tau and Amyloid Plasma Biomarkers	
246		in Alzheimer's Disease Cohorts of Diverse Genetic Ancestries. <i>medRxiv.</i> 2024.	
247	25.	Griswold AJ, Rajabli F, Gu T, et al. Tau and Amyloid Plasma Biomarker Analysis in	
248		Alzheimer's Disease Cohorts from Diverse Genetic Ancestries. Alzheimers Dement.	
249		2023;19(S14):e078942.	
250	26.	Ikanga J, Patel SS, Roberts BR, et al. Association of plasma biomarkers with cognitive	
251		function in persons with dementia and cognitively healthy in the Democratic Republic of	
252		Congo. Alzheimers Dement Diagn Assess Dis Monit. 2023 Oct;15(4):e12496.	
253	27.	Lewczuk P, Ermann N, Andreasson U, et al. Plasma neurofilament light as a potential	
254		biomarker of neurodegeneration in Alzheimer's disease. Alzheimers Res Ther.	
255		2018;10(1):71.	
256	28.	Altmann P, Leutmezer F, Zach H, et al. Serum neurofilament light chain withstands	
257		delayed freezing and repeated thawing. <i>Sci Rep.</i> 2020;10(1):19982.	
258			
259	Legen	ds:	
260	<b>Figure 1:</b> Plasma sampling, processing, and biomarkers analysis workflow.		
261	Figure 2: Box plots showing percentage changes of the mean of the 10 individuals of different		
262	AD blood biomarkers across five timepoints compared to the baseline. *Single solid dash line a		

- 263 0: baseline measurement; \*continuous dash lines: +/- 10% threshold. Black dots: outlier values
- 264 for each biomarkers.
- **Figure 3:** Line graph showing percentage changes of plasma biomarkers individual participants
- 266 across various timepoints.



2

